Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Chinese Firms Win Venture Funding
by Jean-François Tremblay
December 21, 2015
| A version of this story appeared in
Volume 93, Issue 49
The Chinese contract research firm Pharmaron and the biobased chemicals maker Cathay Industrial Biotech have both raised money from Chinese investors. Citic M&A Fund and Legend Capital will provide $280 million to Pharmaron so it can expand its labs to meet growing demand for R&D services from Chinese drug discovery firms. Separately, Cathay drew $135 million from Shanxi Lu’an Mining. Cathay will use the funds to expand its facilities for long-chain dibasic acids, 1,5-pentanediamine, and polyamides, mostly made with renewable materials as feedstocks.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X